David A. Siegel Veracyte, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Veracyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 20,400 shares of VCYT stock, worth $761,736. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,400

Previous 19,500 4.62%

Holding current value

$761,736

Previous $432,000 2.31%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$18.86 - $23.55 $16,974 - $21,195	900 Added 4.62%	20,400 $442,000
Q1 2024 May 15, 2024	SELL	$21.0 - $29.1 $12,600 - $17,460	-600 Reduced 2.99%	19,500 $432,000
Q4 2023 Feb 14, 2024	SELL	$19.72 - $28.68 $5,916 - $8,604	-300 Reduced 1.47%	20,100 $552,000
Q3 2023 Nov 14, 2023	SELL	$22.33 - $29.92 $26,795 - $35,904	-1,200 Reduced 5.56%	20,400 $455,000
Q2 2023 Aug 14, 2023	BUY	$20.96 - $26.99 $71,264 - $91,766	3,400 Added 18.68%	21,600 $550,000
Q1 2023 May 15, 2023	BUY	$20.58 - $27.89 $24,695 - $33,468	1,200 Added 7.06%	18,200 $405,000
Q4 2022 Feb 14, 2023	BUY	$15.31 - $29.94 $4,593 - $8,982	300 Added 1.8%	17,000 $403,000
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $3,315 - $5,580	200 Added 1.21%	16,700 $277,000
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $81,885 - $156,456	5,300 Added 47.32%	16,500 $328,000
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $26,328 - $51,012	1,200 Added 12.0%	11,200 $309,000
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $57,744 - $86,064	1,600 Added 19.05%	10,000 $412,000
Q3 2021 Nov 15, 2021	SELL	$35.62 - $52.97 $4.47 Million - $6.65 Million	-125,600 Reduced 93.73%	8,400 $390,000
Q2 2021 Aug 16, 2021	BUY	$32.94 - $56.62 $3.35 Million - $5.75 Million	101,600 Added 313.58%	134,000 $5.36 Million
Q1 2021 May 17, 2021	BUY	$44.47 - $81.38 $1.44 Million - $2.64 Million	32,400 New	32,400 $1.74 Million
Q4 2020 Feb 16, 2021	SELL	$32.49 - $61.88 $490,599 - $934,388	-15,100 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$26.73 - $35.67 $2.18 Million - $2.9 Million	-81,400 Reduced 84.35%	15,100 $491,000
Q2 2020 Aug 14, 2020	SELL	$19.49 - $28.11 $411,238 - $593,121	-21,100 Reduced 17.94%	96,500 $2.5 Million
Q1 2020 May 15, 2020	SELL	$16.13 - $30.17 $1.85 Million - $3.45 Million	-114,400 Reduced 49.31%	117,600 $2.86 Million
Q4 2019 Feb 14, 2020	SELL	$20.78 - $29.99 $3.23 Million - $4.67 Million	-155,600 Reduced 40.14%	232,000 $6.48 Million
Q3 2019 Nov 14, 2019	SELL	$23.87 - $30.93 $494,109 - $640,251	-20,700 Reduced 5.07%	387,600 $9.3 Million
Q2 2019 Aug 14, 2019	BUY	$22.1 - $28.56 $3.26 Million - $4.21 Million	147,500 Added 56.56%	408,300 $11.6 Million
Q1 2019 May 15, 2019	BUY	$12.0 - $25.76 $1.69 Million - $3.64 Million	141,200 Added 118.06%	260,800 $6.53 Million
Q4 2018 Feb 14, 2019	BUY	$9.15 - $14.85 $416,325 - $675,675	45,500 Added 61.4%	119,600 $1.51 Million
Q3 2018 Nov 14, 2018	BUY	$9.55 - $12.64 $482,275 - $638,320	50,500 Added 213.98%	74,100 $708,000
Q2 2018 Aug 14, 2018	BUY	$5.39 - $9.66 $127,203 - $227,976	23,600 New	23,600 $220,000

Others Institutions Holding VCYT

# of Institutions

270

Shares Held

78.7M

Call Options Held

42.3K

Put Options Held

18.2K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.67B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account